Our website is made possible by displaying non-intrusive online advertisements to our visitors.
Please consider supporting us by disabling or pausing your ad blocker.
On Genting’s 20.33%-owned TauRx, it said positive data from TauRx’s HMTM Phase Three trial may set a milestone towards securing authorities’ approval, which could potentially fetch RM3.45 per share monetisation value for Genting’s stake in TauRx.